CRISPR/Cas9-mediated knockdown of tRNAiMet inhibits glioblastoma cell proliferation and the replenishing of ectopic tRNAiMet partly rescues the Sox4-mediated proliferation inhibition [91]. The gene discussed is SOX4; the disease is glioblastoma.